Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Must Reads In B Cell Lymphoma

B Cell Lymphoma for September/October 2019

Consider renal function in TLS risk assessment of venetoclax-treated CLL,

Pembrolizumab shows promise for relapsed/refractory PMBCL,

PJP prophylaxis may be unnecessary for CLL patients on BTK inhibitors,

Ibrutinib linked to hypertension in B-cell malignancies,

Best treatment approach for early stage follicular lymphoma is unclear,

More must reads

B Cell Lymphoma for July/August 2019

Ibrutinib-Rituximab Induction Yields ‘Unprecedented’ Responses in MCL,

Obinutuzumab-lenalidomide combo shows promise in relapsed/refractory FL,

Zanubrutinib may be poised to challenge ibrutinib for CLL,

Ibrutinib/Rituximab Effective, Safe as Frontline Treatment for Older Patients With MCL,

Low-Dose Radiation Therapy Looks Effective in Hard-to-Treat MCL,

More must reads

B Cell Lymphoma for May/June 2019

5F9 Plus Rituximab Take a Bite Out of Drug-Resistant NHL,

‘Encouraging’ Responses Seen With Durvalumab Plus R-CHOP in DLBCL,

Chemo-Free Regimen Looks Promising in Poor-Prognosis DLBCL,

DA-EPOCH-R Appears More Toxic Than Standard R-CHOP in DLBCL,

Polatuzumab Outperforms Pinatuzumab in Non-Hodgkin Lymphoma,

More must reads

B Cell Lymphoma for March/April 2019

Idelalisib shows long-term safety, efficacy for relapsed CLL,

High-dose MTX-based chemo is well tolerated in older PCNSL patients,

RIT consolidation may be an option for unfit MCL patients,

In situ vaccination produced responses in indolent NHL,

Early data support R-BAC for post-BTKi mantle cell lymphoma,

More must reads

B Cell Lymphoma for January/February 2019

Case studies shed light on treatment for rare form of MCL , Mori S et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):e93-7.

Histopathological clues for differentiating follicular lymphomas, Servitje O et al. J Cutan Pathol. 2019;46:182-9.

Single agent daratumumab is not an option in B-cell lymphomas, Salles G et al. Clin Lymphoma Myeloma Leuk. 2019 Jan 2. doi: 10.1016/j.clml.2018.12.013.

Ibrutinib combo advances in CNS lymphoma, Grommes C et al. Blood. 2019;133(5):436-45.

Best frontline options for advanced follicular lymphoma, Shah NN et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):95-102.
More must reads

Pages